Refine
Document Type
- Article (1)
- Conference Proceeding (1)
- Review (1)
Institute
- Kulturwissenschaften (2)
- Medizin (1)
-
[Rezension zu:] Set in Stone: The Face in Medieval Sculpture (New York, The Metropolitan Museum of Art, 26.11.2006 - 19.02.2007)
(2006)
- Rezension zu: Little, Charles T.; Sauerländer, Willibald (Hrsg.): Set in stone. The face in medieval sculpture ; [in conjuction with the Exhibition "Set in Stone: The Face in Medieval Sculpture", held at the Metropolitan Museum of Art, New York, from September 26, 2006 - February 18, 2007], New Haven, Conn. [u.a.]: Yale University Press 2006 ISBN-10: 1-58839-192-2, XVI, 222 S., 50 USD
-
[Tagungsbericht zu:] Das Atrium von San Marco in Venedig. Die Genese der Genesismosaiken : Bad Homburg, Forschungskolleg Humanwissenschaften, 22. - 23.06.2012
(2012)
- Bericht der Organisatoren: Die Tagung wollte ein Zeichen setzen: ein Zeichen, dass es geboten sei, sich erneut der Cotton Genesis und ihrem ausdrücklichsten mittelalterlichen Nachfahren, den Schöpfungsmosaiken der Vorhalle von San Marco in Venedig, zuzuwenden. Die Diskussion dieser Verbindung von frühchristlichen Illuminationen, die nur noch in wenigen verkohlten Fragmenten überliefert sind, mit den mittelalterlichen Mosaiken ist seit der Entdeckung durch Johan Jakob Tikkanen 1889 geführt worden. Sie kam 1986 mit der Edition der Cotton Genesis durch Kurt Weitzmann und Herbert Kessler zu einem vorläufigen Abschluss. Die Mosaiken erschienen als weitgehend getreue Kopie der Buchmalereien der Handschrift, die dabei allein redaktionelle, aber keine konzeptionelle Veränderungen durch die Mosaizisten erfahren hätten...
-
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
(2011)
- Introduction Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard of care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard of care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods Patients who received rituximab having shown an inadequate response to standard of care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases. The main outcome measures were safety and clinical response, as judged at the discretion of the investigators. Results A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated vasculitides, 15.1% multiple sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2440 mg of rituximab over a median (range) of 194 (180 to 1407) days. The overall rate of serious infections was 5.3 per 100 patient-years during rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6% showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab generally had a positive effect on patient well-being (physician's visual analogue scale; mean improvement from baseline of 12.1 mm). Conclusions Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies. Additional file 1: Supplemental tables. Table A1. Duration of follow-up from first rituximab infusion to last control visit by diagnosis. Table A2. Number of rituximab infusions by diagnosis.
